BioNTech Q3 2026 swings to net profit of €184.5 million

Bitget2026/11/03 11:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioNTech swung to a third-quarter 2026 net profit of €184.5 million from a year-earlier loss of €28.7 million.
Revenues fell 15% year over year to €1.29 billion due to lower demand for COVID-19 vaccines.
Research and development expenses rose 32% year over year to €748.1 million, driven by late-stage oncology development costs and intangible-asset impairments.
A planned global Phase 3 trial will evaluate pumitamig with Gilead’s sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030645PRIMZONEFULLFEED1001301499) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioNTech Q3 2026 swings to net profit of €184.5 million

You may also like

Crypto prices